FTC Dems want section 5 used on drug prices
A Federal Trade Commission report on the agency’s authority to limit price increases for off-patent drugs has drawn disagreement from two commissioners.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10